Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2124 | Levamisole and isoprinosine Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
The use of both levamisole & Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection
Description: Improvement of fever in degrees celsius
Measure: COVID 19 induced fever in both groups Time: 4 weeksDescription: improvement of dyspnea by normalization of respiratory rate
Measure: COVID 19 induced dyspnea in both groups Time: 4 weeksDescription: PCR of COVID 19 changes from positive to negative
Measure: COVID 19 viral load in both groups Time: 4 weeksDescription: CRP in mg/dL
Measure: laboratory clearance in both groups: CRP in mg/dL Time: 4 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports